| Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. | |
| | |
MedLine Citation:
|
PMID: 19617343 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of neuroendocrine tumor. Because detection of distant metastases has a major impact on treatment, early diagnosis of metastatic spread is of great importance. So far, no standard procedure has become established for the early diagnosis of bone metastases from neuroendocrine tumor. We compared the diagnostic value of CT with that of the novel somatostatin analog (68)Ga-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC) in the detection of such metastases. METHODS: Fifty-one patients (22 women and 29 men; age range, 32-87 y) with histologically verified neuroendocrine tumor were included in this study. PET scans were fused with CT scans using a vacuum fixation device. (18)F-NaF or (99m)Tc-dicarboxypropane diphosphonate bone scans or clinical follow-up served as the reference standard. RESULTS: Twelve of the 51 patients had no evidence of bone metastases on any of the available imaging modalities, and 37 patients had (68)Ga-DOTATOC PET results true-positive for bone metastases. (68)Ga-DOTATOC PET results were true-negative for 12 patients, false-positive for one, and false-negative for another, resulting in a sensitivity of 97% and a specificity of 92%. (68)Ga-DOTATOC PET detected bone metastases at a significantly higher rate than did CT (P < 0.001). Furthermore, conventional bone scans confirmed the results of somatostatin receptor PET but did not reveal additional tumors in any patients. CONCLUSION: (68)Ga-DOTATOC PET is a reliable, novel method for the early detection of bone metastases in patients with neuroendocrine tumor. Our results show that CT and conventional bone scintigraphy are less accurate than (68)Ga-DOTATOC PET in the primary staging or restaging of neuroendocrine tumor. |
| | |
Authors:
|
Daniel Putzer; Michael Gabriel; Benjamin Henninger; Dorota Kendler; Christian Uprimny; Georg Dobrozemsky; Clemens Decristoforo; Reto Josef Bale; Werner Jaschke; Irene Johanna Virgolini |
Related Documents
:
|
17892923 - The role of 18f-fdg pet/ct in detecting metastatic deposits of recurrent medullary thyr... 9930463 - Cost-effectiveness of fdg-pet for staging non-small cell lung cancer: a decision analysis. 21403583 - Characterization of thymic lesions with f-18 fdg pet-ct: an emphasis on epithelial tumors. |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article Date: 2009-07-17 |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 50 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-04 Completed Date: 2009-09-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1214-21 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria. daniel.putzer@i-med.ac.at |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Bone Neoplasms / diagnosis*, secondary* Female Humans Male Middle Aged Neuroendocrine Tumors / diagnosis*, secondary* Octreotide / analogs & derivatives*, diagnostic use Organometallic Compounds / diagnostic use* Positron-Emission Tomography / methods* Radiopharmaceuticals / diagnostic use, pharmacokinetics Reproducibility of Results Sensitivity and Specificity Tomography, X-Ray Computed / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Ga(III)-DOTATOC; 0/Organometallic Compounds; 0/Radiopharmaceuticals; 83150-76-9/Octreotide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulati...
Next Document: Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress re...